Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9166
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYang, Tsung-Ying-
dc.contributor.authorHsieh, Ya-Ju-
dc.contributor.authorKao, Li-Ting-
dc.contributor.authorHong Liu, Guan-
dc.contributor.authorLian, Shao-Hsuan-
dc.contributor.authorWang, Liang-Chun-
dc.date.accessioned2024-12-17T03:46:54Z-
dc.date.available2024-12-17T03:46:54Z-
dc.date.issued2022-02-01-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/9166-
dc.description.abstractAbstract Background: Imipenem-relebactam is a new b-lactam and b-lactamase inhibitor combination to treat carbapenem-resistant gram-negative bacteria infections. However,difference in carbapenem resistant mechanisms existed with geographic variations. Objective: To evaluate the susceptibility of imipenem-relebactam to 660 carbapenemnonsusceptible Enterobacteriaceae isolates in Taiwan and to identify the in vivo efficacy with a Caenorhabditis elegans model. Methods: 188 carbapenem-nonsusceptible Escherichia coli isolates and 472 carbapenemnonsusceptible Klebsiella pneumoniae isolates were collected from a national surveillance study in Taiwan. The antimicrobial susceptibility profiles and carbapenemase distributions were determined. An agar dilution method was performed to evaluate the in vitro activities of imipenem monotherapy and imipenem-relebactam combination. Contributions of metallocarbapenemase to imipenem-relebactam susceptibility was investigated via EDTA treatment. A C. elegans model was used to evaluate the in vivo efficacy of imipenem-relebactam combination. Results: 87.8% and 82.2% susceptibility to imipenem-relebactam was observed for 188 carbapenem-nonsusceptible E. coli and 472 carbapenem-nonsusceptible K. pneumoniae, respectively. However, poor activities of imipenem-relebactam was observed against 23 metallo-carbapenemase producers tested in this study. In the in vivo C. elegans model, imipenem-relebactam significantly rescued nematodes from the infection of a blaKPC-producing K. pneumoniae isolate. Conclusion: Our study supports that imipenem-relebactam is a potential therapy against carbapenem-nonsusceptible Enterobacteriaceae, and to our knowledge, this is the first report of evaluation for imipenem-relebactam efficacy against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan.en_US
dc.language.isoenen_US
dc.publisherElsevier Taiwan LLCen_US
dc.subjectImipenem;en_US
dc.subjectRelebactam;en_US
dc.subjectCarbapenemnonsusceptible;en_US
dc.subjectEnterobacteriaceae;en_US
dc.subjectin vivo;en_US
dc.subjectCaenorhabditis elegansen_US
dc.titleActivities of imipenem-relebactam combination against carbapenemnonsusceptible Enterobacteriaceae in Taiwanen_US
dc.typeArticleen_US
Appears in Collections:VOL 55 NO 1 2022

Files in This Item:
File Description SizeFormat 
86-94.pdf574.68 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.